Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 06 2021
Historique:
received: 03 06 2020
accepted: 06 01 2021
pubmed: 30 1 2021
medline: 15 12 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

The extrafollicular immune response is essential to generate a rapid but transient wave of protective antibodies during infection. Despite its importance, the molecular mechanisms controlling this first response are poorly understood. Here, we demonstrate that enhanced Cxcr4 signaling caused by defective receptor desensitization leads to exacerbated extrafollicular B-cell response. Using a mouse model bearing a gain-of-function mutation of Cxcr4 described in 2 human hematologic disorders, warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome and Waldenström macroglobulinemia, we demonstrated that mutant B cells exhibited enhanced mechanistic target of rapamycin signaling, cycled more, and differentiated more potently into plasma cells than wild-type B cells after Toll-like receptor (TLR) stimulation. Moreover, Cxcr4 gain of function promoted enhanced homing and persistence of immature plasma cells in the bone marrow, a phenomenon recapitulated in WHIM syndrome patient samples. This translated in increased and more sustained production of antibodies after T-independent immunization in Cxcr4 mutant mice. Thus, our results establish that fine-tuning of Cxcr4 signaling is essential to limit the strength and length of the extrafollicular immune response.

Identifiants

pubmed: 33512437
pii: S0006-4971(21)00176-2
doi: 10.1182/blood.2020007450
pmc: PMC8176768
doi:

Substances chimiques

CXCR4 protein, mouse 0
Receptors, CXCR4 0
mTOR protein, mouse EC 2.7.1.1
TOR Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3050-3063

Références

Br J Haematol. 2019 Nov;187(3):356-363
pubmed: 31267520
Blood. 2014 Jun 26;123(26):4120-31
pubmed: 24711662
Immunity. 2013 Nov 14;39(5):912-24
pubmed: 24184055
Ther Adv Hematol. 2011 Aug;2(4):267-72
pubmed: 23556094
Front Immunol. 2017 Sep 04;8:1068
pubmed: 28928741
Semin Immunol. 2008 Feb;20(1):49-58
pubmed: 18222702
Blood. 2005 Mar 15;105(6):2449-57
pubmed: 15536153
J Immunol. 2009 Jan 1;182(1):604-12
pubmed: 19109194
Blood. 2012 Jun 14;119(24):5722-30
pubmed: 22438253
Eur J Immunol. 1990 Oct;20(10):2277-83
pubmed: 1700753
J Exp Med. 2004 Oct 18;200(8):967-77
pubmed: 15492122
Immunity. 2016 Jan 19;44(1):116-130
pubmed: 26795247
Best Pract Res Clin Haematol. 2016 Jun;29(2):148-155
pubmed: 27825460
Nat Immunol. 2016 Oct;17(10):1216-1225
pubmed: 27500631
Blood Adv. 2019 Oct 8;3(19):2800-2803
pubmed: 31570491
J Exp Med. 2003 Feb 17;197(4):461-73
pubmed: 12591904
Blood. 2014 Mar 13;123(11):1637-46
pubmed: 24366360
J Exp Med. 2004 Nov 1;200(9):1145-56
pubmed: 15520246
Blood Adv. 2018 Nov 13;2(21):2937-2946
pubmed: 30401751
Blood. 2018 Apr 5;131(14):1545-1555
pubmed: 29378696
Nat Protoc. 2015 Dec;10(12):1904-14
pubmed: 26513669
Ann Hematol. 2017 Jun;96(6):971-976
pubmed: 28280994
Annu Rev Physiol. 2007;69:451-82
pubmed: 17037978
Blood. 2009 Nov 12;114(20):4432-40
pubmed: 19767510
Immunology. 2004 Aug;112(4):509-20
pubmed: 15270721
Leukemia. 2015 Jan;29(1):169-76
pubmed: 24912431
Exp Hematol. 2005 Apr;33(4):460-8
pubmed: 15781337
N Engl J Med. 2015 Aug 6;373(6):584-6
pubmed: 26244327
Cell Rep. 2016 Sep 27;17(1):193-205
pubmed: 27681431
Blood. 2014 May 1;123(18):2791-6
pubmed: 24553177
Immunol Rev. 2003 Aug;194:8-18
pubmed: 12846803
J Immunol. 2012 Jun 1;188(11):5389-96
pubmed: 22529295
Clin Immunol. 2010 Jun;135(3):412-21
pubmed: 20226738
Nat Immunol. 2004 Sep;5(9):943-52
pubmed: 15300245
J Immunol. 2012 Jan 1;188(1):57-67
pubmed: 22116821
Clin Cancer Res. 2016 Mar 15;22(6):1480-8
pubmed: 26490317
Blood. 2004 Jul 15;104(2):444-52
pubmed: 15026312
Nat Immunol. 2004 Jan;5(1):55-63
pubmed: 14647274
Blood. 2004 Aug 1;104(3):784-7
pubmed: 15069012
Vaccine. 2010 Jul 5;28(30):4837-41
pubmed: 20472031
J Immunol. 2003 Jun 15;170(12):5851-60
pubmed: 12794110
Blood. 2016 Sep 8;128(10):1321-8
pubmed: 27432877
J Exp Med. 2001 Jul 2;194(1):45-56
pubmed: 11435471
J Immunol. 2003 Feb 1;170(3):1267-73
pubmed: 12538685
Cell. 2010 Nov 12;143(4):592-605
pubmed: 21074050
Immunology. 1991 Apr;72(4):544-9
pubmed: 1709916

Auteurs

Nagham Alouche (N)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Inflammation, Chemokines and Immunopathology, INSERM, Université Paris-Sud, Université Paris-Saclay, Clamart, France.

Amélie Bonaud (A)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Vincent Rondeau (V)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Rim Hussein-Agha (R)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.

Julie Nguyen (J)

Inflammation, Chemokines and Immunopathology, INSERM, Université Paris-Sud, Université Paris-Saclay, Clamart, France.

Valeria Bisio (V)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Mélanie Khamyath (M)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Etienne Crickx (E)

Institut Necker-Enfants Malades-INSERM U1151/CNRS UMR8633, Faculté de Médecine, Université Paris Descartes, Paris, France.

Niclas Setterblad (N)

Institut de Recherche Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; and.

Nicolas Dulphy (N)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Matthieu Mahevas (M)

Institut Necker-Enfants Malades-INSERM U1151/CNRS UMR8633, Faculté de Médecine, Université Paris Descartes, Paris, France.

David H McDermott (DH)

Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Philip M Murphy (PM)

Molecular Signaling Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Karl Balabanian (K)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Marion Espéli (M)

Ecotaxie, Microenvironnement et Developpement Lymphocytaire (EMiLy), INSERM U1160, Institut de Recherche Saint Louis, Université de Paris, Paris, France.
Groupement de Recherche 3697 "Microenvironment of Tumor Niches," Centre National de la Recherche Scientifique (CNRS), Micronit, France.
OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH